Therefore, the close interplay between SHBG levels and risk factors involved in the pathogenesis of NAFLD, obesity and MetS suggests SHBG as a potential therapeutic target in the management of these diseases [25]. The gene discussed is SHBG; the disease is obesity due to melanocortin 4 receptor deficiency.